In reply

Affiliations

¹ Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, German Central Committee against Tuberculosis (DZK), Berlin, Germany.
² Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany. silvan.vesenbeckh@helios-kliniken.de.
³ Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
⁴ Institute of Microbiology, HELIOS Klinikum Emil von Behring, Berlin, Germany.
⁵ Institute of Molecular Biology, HELIOS Klinikum Emil von Behring, Berlin, Germany.

Comment

Ralf Otto-Knapp et al. Int J Tuberc Lung Dis. 2017.

. 2017 Jan 1;21(1):123.

doi: 10.5588/ijtld.16.0689-2.

¹ Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, German Central Committee against Tuberculosis (DZK), Berlin, Germany.
² Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany. silvan.vesenbeckh@helios-kliniken.de.
³ Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
⁴ Institute of Microbiology, HELIOS Klinikum Emil von Behring, Berlin, Germany.
⁵ Institute of Molecular Biology, HELIOS Klinikum Emil von Behring, Berlin, Germany.

No abstract available

Comment on

Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation.
Otto-Knapp R, Vesenbeckh S, Schönfeld N, Bettermann G, Roth A, Bauer T, Rüssmann H, Mauch H. Otto-Knapp R, et al. Int J Tuberc Lung Dis. 2016 Sep;20(9):1275-6. doi: 10.5588/ijtld.16.0148. Int J Tuberc Lung Dis. 2016. PMID: 27510258 No abstract available.
Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.
Alsultan A, Peloquin CA. Alsultan A, et al. Int J Tuberc Lung Dis. 2017 Jan 1;21(1):121-123. doi: 10.5588/ijtld.16.0689. Int J Tuberc Lung Dis. 2017. PMID: 28157477 No abstract available.